Confirmed Control Closed Transaction verified BiopharmaceuticalsCannabinoid MedicinesCannabis Based Epilepsy DrugLife Sciences Cannabinoid Medicines
GW Pharmaceuticals acquired by Jazz Pharmaceuticals
Jazz Pharmaceuticals acquired GW Pharmaceuticals, a life sciences cannabinoid medicines brand on Feb 3, 2021. The transaction value is shown as USD 7.2bn. Public sources confirm the deal; valuation inputs may include estimates where transaction materials do not disclose the full economics.
Transaction summary
- Target
- GW Pharmaceuticals
- Acquirer
- Jazz Pharmaceuticals
- Seller
- -
- Announced
- 2021-02-03
- Geography
- -
- Tags
- BiopharmaceuticalsCannabinoid MedicinesCannabis Based Epilepsy DrugLife Sciences Cannabinoid Medicines
- Type
- Acquisition
- Deal type
- Control
- Stake acquired
- -
- First added
- 2026-06-19
- Latest update
- 2026-06-19
Value and multiples
Price / value
USD 7.2B
Transaction value | USD
Basis: Public source
EV / revenue
-
Period not stated
Basis: FundComb estimate
EV / EBITDA
12.9x
EBITDA basis not stated
Basis: FundComb estimate
Basis
- USD 7.2bn transaction value is treated as publicly disclosed or derived directly from public source data.
- EV / EBITDA is shown as 12.9x based on the available comp inputs.
- EBITDA and multiple inputs are not fully disclosed in public transaction materials reviewed; treat the multiple as an estimate.
- EBITDA basis was not stated in the source material.
Source summary
No public source summary has been published for this transaction yet.